Artiva Biotherapeutics (ARTV) Competitors $10.72 +0.58 (+5.72%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends ARTV vs. CRGX, CGEM, SANA, RLAY, IMTX, REPL, TRML, ALGS, ADPT, and HUMAShould you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include CARGO Therapeutics (CRGX), Cullinan Therapeutics (CGEM), Sana Biotechnology (SANA), Relay Therapeutics (RLAY), Immatics (IMTX), Replimune Group (REPL), Tourmaline Bio (TRML), Aligos Therapeutics (ALGS), Adaptive Biotechnologies (ADPT), and Humacyte (HUMA). These companies are all part of the "biological products, except diagnostic" industry. Artiva Biotherapeutics vs. CARGO Therapeutics Cullinan Therapeutics Sana Biotechnology Relay Therapeutics Immatics Replimune Group Tourmaline Bio Aligos Therapeutics Adaptive Biotechnologies Humacyte CARGO Therapeutics (NASDAQ:CRGX) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations. Do analysts rate CRGX or ARTV? CARGO Therapeutics presently has a consensus target price of $30.33, indicating a potential upside of 48.91%. Artiva Biotherapeutics has a consensus target price of $21.25, indicating a potential upside of 98.23%. Given Artiva Biotherapeutics' higher possible upside, analysts clearly believe Artiva Biotherapeutics is more favorable than CARGO Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CARGO Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CRGX or ARTV more profitable? Artiva Biotherapeutics' return on equity of 0.00% beat CARGO Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CARGO TherapeuticsN/A -50.68% -38.69% Artiva Biotherapeutics N/A N/A N/A Does the MarketBeat Community favor CRGX or ARTV? CARGO Therapeutics received 4 more outperform votes than Artiva Biotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformCARGO TherapeuticsOutperform Votes11100.00% Underperform VotesNo VotesArtiva BiotherapeuticsOutperform Votes7100.00% Underperform VotesNo Votes Do institutionals and insiders believe in CRGX or ARTV? 93.2% of CARGO Therapeutics shares are held by institutional investors. 1.4% of CARGO Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has better earnings and valuation, CRGX or ARTV? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCARGO TherapeuticsN/AN/A-$98.15M-$50.75-0.40Artiva BiotherapeuticsN/AN/AN/AN/AN/A Does the media refer more to CRGX or ARTV? In the previous week, CARGO Therapeutics and CARGO Therapeutics both had 1 articles in the media. CARGO Therapeutics' average media sentiment score of 0.47 beat Artiva Biotherapeutics' score of -1.00 indicating that CARGO Therapeutics is being referred to more favorably in the media. Company Overall Sentiment CARGO Therapeutics Neutral Artiva Biotherapeutics Negative SummaryCARGO Therapeutics beats Artiva Biotherapeutics on 5 of the 8 factors compared between the two stocks. Ad Porter & CompanyBanking failure dead aheadIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTV vs. The Competition Export to ExcelMetricArtiva BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$260.39M$3.15B$5.33B$8.52BDividend YieldN/A1.77%5.07%4.13%P/E RatioN/A16.44128.4016.13Price / SalesN/A321.081,491.7792.21Price / CashN/A149.0539.5634.18Price / BookN/A4.024.765.07Net IncomeN/A-$42.25M$118.92M$225.46M7 Day Performance2.49%1.81%-0.39%0.07%1 Month Performance-30.48%8.56%6.06%3.93%1 Year PerformanceN/A35.10%38.23%32.51% Artiva Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTVArtiva BiotherapeuticsN/A$10.72+5.7%$21.25+98.2%N/A$260.39MN/A0.0081Negative NewsGap UpCRGXCARGO Therapeutics1.6943 of 5 stars$21.93+4.7%$30.33+38.3%N/A$1.01BN/A-0.43116Short Interest ↑CGEMCullinan Therapeutics2.193 of 5 stars$16.15+1.2%$31.67+96.1%+70.0%$930.79M$18.94M-5.2830Analyst RevisionNews CoverageSANASana Biotechnology2.6534 of 5 stars$3.92+4.3%$14.25+263.5%+18.4%$872.08MN/A-3.41328Gap UpRLAYRelay Therapeutics3.2161 of 5 stars$6.03+0.2%$21.11+250.1%-14.5%$807.36M$25.55M-2.39304Upcoming EarningsNews CoverageIMTXImmatics1.5926 of 5 stars$9.28+0.2%$17.50+88.6%+19.6%$785.63M$70.87M-10.43260Short Interest ↑REPLReplimune Group3.8735 of 5 stars$12.05+2.7%$16.80+39.4%-16.7%$720.40MN/A-3.69210Upcoming EarningsTRMLTourmaline Bio3.453 of 5 stars$27.45+3.2%$61.00+122.2%+52.7%$703.82MN/A-7.4644ALGSAligos Therapeutics4.6842 of 5 stars$8.87+5.6%$75.00+745.5%-49.1%$692.84M$7.97M-0.4390Upcoming EarningsHigh Trading VolumeADPTAdaptive Biotechnologies3.4335 of 5 stars$4.67+4.9%$6.25+33.8%+19.6%$688.21M$168.77M-3.18709Upcoming EarningsHUMAHumacyte3.1842 of 5 stars$5.42-3.0%$10.00+84.5%+170.9%$645.44M$1.57M-4.30150News Coverage Related Companies and Tools Related Companies CRGX Alternatives CGEM Alternatives SANA Alternatives RLAY Alternatives IMTX Alternatives REPL Alternatives TRML Alternatives ALGS Alternatives ADPT Alternatives HUMA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARTV) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
